SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea
· Delayed Price · Currency is KRW 98,100
-4,800 (-4.66%)
At close: Mar 9, 2026
SK Biopharmaceuticals Revenue
SK Biopharmaceuticals had revenue of 191.73B KRW in the quarter ending September 30, 2025, with 40.35% growth. This brings the company's revenue in the last twelve months to 675.41B, up 32.09% year-over-year. In the year 2024, SK Biopharmaceuticals had annual revenue of 547.60B with 54.30% growth.
Revenue (ttm)
675.41B
Revenue Growth
+32.09%
P/S Ratio
11.37
Revenue / Employee
2.75B
Employees
246
Market Cap
7,682.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 547.60B | 192.70B | 54.30% |
| Dec 31, 2023 | 354.89B | 108.71B | 44.16% |
| Dec 31, 2022 | 246.18B | -172.47B | -41.20% |
| Dec 31, 2021 | 418.64B | 392.65B | 1,510.23% |
| Dec 31, 2020 | 26.00B | -97.85B | -79.01% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LigaChem Biosciences | 159.27B |
| HLB Co., Ltd. | 80.73B |
| Peptron | 6.19B |
| Voronoi | 7.49B |
| OliX Pharmaceuticals | 10.18B |
| D&D Pharmatech | 8.36B |
| PharmaResearch | 496.03B |
| SK bioscience | 624.03B |